Direct-to-consumer marketing to people with hemophilia

The manner in which pharmaceutical companies market their products to people who have hemophilia appears unprecedented and direct-to-consumer marketing should be examined by regulators, say researchers who reviewed documents, including consumer-oriented materials, produced by the makers of hemophilia treatment products.